These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328 [TBL] [Abstract][Full Text] [Related]
5. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ; Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200 [TBL] [Abstract][Full Text] [Related]
6. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. Schneider JL; Zhao WK; Corley DA Dig Dis Sci; 2015 Feb; 60(2):436-43. PubMed ID: 25213077 [TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456 [TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Wang F; Lv ZS; Fu YK Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737 [TBL] [Abstract][Full Text] [Related]
9. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Tsibouris P; Hendrickse MT; Isaacs PE Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913 [TBL] [Abstract][Full Text] [Related]
10. Germline variant in MSX1 identified in a Dutch family with clustering of Barrett's esophagus and esophageal adenocarcinoma. van Nistelrooij AMJ; van Marion R; van Ijcken WFJ; de Klein A; Wagner A; Biermann K; Spaander MCW; van Lanschot JJB; Dinjens WNM; Wijnhoven BPL Fam Cancer; 2018 Jul; 17(3):435-440. PubMed ID: 29134539 [TBL] [Abstract][Full Text] [Related]
17. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286 [TBL] [Abstract][Full Text] [Related]
18. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma. Wang X; Li X; Cheng Y; Sun X; Sun X; Self S; Kooperberg C; Dai JY Hum Genomics; 2015 Sep; 9(1):22. PubMed ID: 26374103 [TBL] [Abstract][Full Text] [Related]
19. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Li X; Paulson TG; Galipeau PC; Sanchez CA; Liu K; Kuhner MK; Maley CC; Self SG; Vaughan TL; Reid BJ; Blount PL Cancer Prev Res (Phila); 2015 Sep; 8(9):845-56. PubMed ID: 26130253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]